• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Any buyers yet









Heard they were down to the final three contenders for a majority owner. Apparently, Wolters Kluwer wants to hang on to a minority part.

Lord knows why... the leadership team are morons, especially when it comes to the sales/marketing part.
 
















Having worked deep in the inner circles of the "company" I can tell you that whomever invests, or, aquires better do their home work. I would question all numbers. Sr. Mgt. is the worst I have ever worked with.

Many of their contracts are done through representing "false" data during RFPs which is how they sometimes win business. In the end they do not deliver what is represented in final contract if they are luck enough to win RFP.

I have seen some funny things done that would not look to good in a court of law...both in personal management AND $ with clients.
 








Unfortunately STG is going to dessimate Wolters Kluwer Pharma Solutions like they did to IRI many years back....already had a reduction in force of 40 people and will outsource all operations to their India facility....if I was still there I would be looking to get out fast!